It is thought that by applying the correct amount of cannabis, the cannabinoids can help with the promotion of lipids which help fight chronic skin conditions including acne and psoriasis. Some also claim that cannabis oil has the power to remove wrinkles and skin spots. While we wouldn’t bank on it being the “anti-aging” miracle, it is helping millions of people worldwide deal with a variety of skin diseases including eczema and rosacea.
Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.
There are a number of possible side effects to using CBD oil, such as fatigue, dry mouth, lightheadedness, hypotension, and impaired motor functions. However, when used in moderate amounts, most people do not experience these side effects, and none of them are known for being fatal or particularly dangerous. More than 20,000 studies have been done in the past 15 years on cannabis, hemp, and cannabinoids, and the results have been overwhelmingly supportive of the therapeutic potential and viability of CBD oil. That being said, some people should be cautious before using this powerful oil.
This study investigated how CBD could affect subjects with liver injuries resulting from chronic and binge alcohol consumption. CBD was given to subjects (in this case, mice and human blood samples) that had been fed alcohol. In short, the analysis demonstrated that CBD lessened the elevated liver enzymes and the increased liver triglyceride. It also reduced fat droplet accumulation.
Over the past few years, increasing public and political pressure has supported legalization of medical marijuana. One of the main thrusts in this effort has related to the treatment of refractory epilepsy—especially in children with Dravet syndrome—using cannabidiol (CBD). Despite initiatives in numerous states to at least legalize possession of CBD oil for treating epilepsy, little published evidence is available to prove or disprove the efficacy and safety of CBD in patients with epilepsy. This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy, and highlights issues related to the use of currently available CBD products.
A number of difficulties exist in evaluating published data on CBD or marijuana use for epilepsy. The extremely limited published studies were small, poorly described, and not well designed. Contributing to the difficulty of interpreting published studies, CBD products are not produced under the guidance of good manufacturing practices (GMP) and are not subject to regulations governing labeling, purity, and reliability. In other words, currently, there is no guarantee of consistency between products, or even differing lots produced by the same manufacturer. Without independent testing (e.g. USP certification) of CBD products for content and purity, as well as bioavailability testing of specific products, uncertainty surrounds the use of available CBD products in routine clinical settings.
Pharmacology published a study in 2016 looking at medical marijuana for migraines, specifically in relation to its effects on serotonin, with very positive results. You’ll notice that neither study looked at CBD in isolation from other cannabinoids (which is an issue with a lot of research on CBD and pain). Truthfully, the research on CBD alone just isn’t sufficient to make any pronouncements about its effects on headache pain.
These reports suffered from a number of design flaws, including incomplete baseline quantification of baseline seizure frequency, indeterminate time periods for outcome determination and, in some cases, inadequate (or missing) statistical analysis—in general, a lack of sufficient detail to adequately evaluate and interpret the findings. Limitations aside, several studies did report that administration of adjunctive CBD did not result in meaningful changes in seizure frequency (11–13).
Simply place the CBD Vape Oil in the designated tank (cartridge), turn on the vaporizer, and smoke the CBD vapor. The great thing about taking CBD vaporized is that it works very fast. The bioavailability is very high, which means that a very large part of the CBD being used is absorbed by the body. The CBD gets into the bloodstream very fast through the absorption in the lungs.
Our bodies are thought to produce endocannabinoids by the billions every day. “We always thought the ‘runner’s high’ was due to the release of dopamine and endorphins. But now we know the euphoria is also from an endocannabinoid called anandamide,” its name derived from the Sanskrit word for bliss, says Joseph Maroon, MD, clinical professor and vice chairman of neurosurgery at the University of Pittsburgh Medical Center. We produce these natural chemicals all day, but they fade quickly because enzymes pop up to destroy them. That’s where CBD comes in: By blocking these enzymes, CBD allows the beneficial compounds to linger.
While it is still classed illegal on a Federal level, individual U.S. states have adopted a more lenient policy towards this plant and some states now allow it for recreational use. The easing up of state laws has also allowed researchers to explore this miraculous plant and only recently has it been found to be an effective treatment for a variety of medical problems due to its CBD oil benefits. From cancer, anorexia, pain and inflammation management it seems like medical marijuana is placing a strong footing within the medical industry.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
The cannabis plant contains a unique group of carbon compounds often referred to a phytocannabinoids. The most common ingredient is THC, which creates the euphoric high effect. Due to the THC element in the plant, marijuana is often associated with a stoner stigma of people only wanting to get high. But that is far from the truth. Cannabis also contains other medicinal compounds including cannabinol, cannabigerol, cannabidiol, and cannabichromene.
Many people are tempted to believe that products that contain CBD only are the best, thinking that using just CBD alone is a more effective treatment. While products that contain single-molecule CBD, meaning that you won’t find any other compounds, are already provided as medicines, they are not exactly more efficient than whole plant extract CBD oil, when it comes to therapeutic effects.